BioImagene,
Inc., the leading provider of end-to-end digital
pathology solutions, today announced the availability of Companion
Algorithms™ for colon cancer in their Virtuoso™ Digital Pathology
Software. BioImagene’s Companion
Algorithms are unique in the digital pathology industry as they are
specific to a biomarker and a tissue type. Therefore, pathologists are
not faced with the challenges of customizing generic algorithms in order
to make them work.
The new colon panel will assist in the quantitation of
immunohistochemistry stains for four mismatch repair biomarkers. These
biomarkers are MLH1, MSH2, MSH6 and PMS2. Approximately 10-15 percent of
sporadic colon cancers exhibit microsatellite instability and recent
studies suggest that testing for mismatch repair protein expression may
provide prognostic and therapeutic information [Ward et al. J Pathol
2005; 207: 377–84].
Dr.
Bikash Sabata, Chief Technology Officer (CTO) said, ”BioImagene’s
iAnalytics™ platform allows us to rapidly develop and validate
sophisticated Companion Algorithms. Virtuoso is the only digital
pathology software in the industry today to offer a complete breast,
prostate and a colon panel.” BioImagene currently offers more than 100
Companion Algorithms, including the breast panel consisting of HER2,
ER/PR and p53; Ki67 for brain, GI and prostate cancers; CD138 for
multiple myeloma; and CD3/CD20 for lymphoma.